$PBYI

HUNT DOUGLAS M sold $70K of PBYI

HUNT DOUGLAS M (See Remarks) sold 8,460 shares of PUMA BIOTECHNOLOGY, INC. (PBYI) at $8.26 on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · HUNT DOUGLAS M
Published Jul 8, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PBYI
Neutral
high confidence
Mentioned
$PBYI
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PBYINeutralLow
01

Why it matters

The disclosed sale is pre-arranged under Rule 10b5-1, which generally lowers the informational content about near-term company prospects.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new operational, financial, or regulatory catalyst in the text.

03

What to watch

The article provides only the sale details, not context like option exercises, tax-motivated sales, or whether other insiders also sold/bought around the same window.

Relevance 2/10Novelty 3/10Timing: filed 2026-07-08, transaction dated 2026-07-06

Background

The article is an SEC Form 4 insider transaction report for PUMA Biotechnology, Inc. (PBYI).

Company-level read

Ticker impact

$PBYINeutralHigh confidence
Context

PBYI Form 4 shows officer Hunt Douglas M sold 8,460 shares at $8.2630 on 2026-07-06 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely limited to sentiment and should fade unless accompanied by other news.

Evidence & confidence

The filing is a Form 4 insider transaction with an explicitly stated pre-arranged Rule 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.

Market effects

No sector-level implications disclosed; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, the market may overreact; the disclosure could be mechanically scheduled rather than a bearish signal.

Key entities

  • PUMA BIOTECHNOLOGY, INC.

    Subject of the Form 4 insider transaction disclosure.

  • HUNT DOUGLAS M

    Officer who sold 8,460 shares at $8.2630 on 2026-07-06 under a 10b5-1 plan.

Related articles

$PBYIMedAI 8/10

Puma Biotechnology Q2 Earnings Call Highlights

Puma Biotechnology (PBYI) reported Q2 earnings call updates. It is advancing Phase II alisertib trials ALISCA-Breast1 and ALISCA-Lung1, amending ALISCA-Breast1 to enroll only 40 mg and 50 mg twice daily, and continuing ALISCA-Lung1 enrollment at 70 mg twice daily. 2026 guidance: net NERLYNX revenue $205M-$209M, net income $17M-$20M. Q3 net NERLYNX $54M-$56M; cash about $93.9M; debt-free.

$PBYIMed

PUMA BIOTECHNOLOGY, INC. (PBYI): Results of Operations and Financial Condition

PUMA BIOTECHNOLOGY, INC. (PBYI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_973970.htm EXHIBIT 99.1 ex_973970.htm Exhibit 99.1 News Release Puma Biotechnology Reports Second Quarter 2026 Financial Results Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX LOS ANGELES, Calif., Aug. 6, 2026 - Puma Biotechnology,